LABORATORY STUDIES AND CLINICAL TRIALS OF CHEMICAL RADIO-SENSITIZERS 



central tumour dose l,100r, would be given by a central tumour dose of 

 X-radiation alone of at least 1,400 r, and probably about 1,500 r. 



In the early stages of this work no effect appeared to be obtained with 

 intravenous Compound I given immediately after the end of the X-radiation 

 of the tumoiu', but this experiment will be repeated. 



Table IV. — Clinical Therapeutic Trial of Compound I as a Radio-sensitizer (Contd.) 



Number of cases surviving 8 months 

 or more after first X-ray treatment/ 

 Total number of cases in each group 

 Group X+I-VS X+I-MS 



(d) Verified as in (a) and (b) but minimum tumour dose 



less than 1,200 r 0/4 0/5 



(None sur\ived (None survived 



more than two more than two 



months) months) 



(e) Male patients with extra-thoracic spread and/or 



metastases in ribs at first X-ray treatment, or with 



syndrome of superior mediastinal obstruction .. 5/26 3/16 



(el) Excluding cases with minimum tumour dose less 



than 1,200 r 4/21 2/11 



(f) Male patients treated surgically at some stage . . 2/7 7/7 



(g) Male patients with diagnosis of carcinoma of the 



bronchus not verified : 



(gl) diagnosis of carcinoma of bronchus i/«/i/oiY'(f .. 0/5 3/5 

 (g2) diagnosis of carcinoma of bronchus unlikely O'" 



disproved 1/5 6/6 



(h) Female patients, all groups except bronchial adenoma 2/9 2/4 



(i) Bronchial adenoma .. .. .. .. .. 0/2 0/1 



(j) No X-ray therapy ; compound only ...... 0/1 



(k) Operable but not treated surgically on account of 



poor general condition . . . . . . . . 2/2 



For the unselected inoperable male patients treated with effective doses of X-radiation 

 in the pooled groups (a), (b), (c) and (el), the proportions surviving 8 months or more 

 after the first X-ray treatment in the series X+I-VS and X+I-MS are respectively 19/42 

 and 5/36 : x'>[i] = 8-64, so that P= 0-003. 



Survival from the first symptom is a rather less sensitive and less objective test. The pro- 

 portions survi\ing 1 1 months or more after the first symptom are respectively (after transfer 

 of the case marked * to the series X+I-MS) for the series X+I-VS, 26/41 and for the series 

 X+I-MS, 14/37 ; x^c[i] = 4-12, so that P=0-0043 and this difference between the two 

 series can be regarded as significant, even after the inclusion of the unfavourable cases in 

 group (el). 



With reference to Table I, the animals were killed when the maximum 

 dimension of the tumour reached 5 • cm or when the animal was look- 

 ing ill and cachectic before that size of the tumour was reached. Under 

 these conditions, there were very few animals with metastases detectable 

 macroscopically, 



CLINICAL TRIALS OF TETR A-SO D lU M- 2 - METH Y L- 1 : 4- N APHTH O- 

 HYDROqUINONE DIPHOSPHATE, COMPOUND I, AS A RADIO-SENSITIZER 



The results in this clinical trial as assessed on 30th June 1954 are summarized 

 in Tables III and IV. These tables are a revision of Table II of my earlier 

 report^ ; the basis for the classification and assessment of the results is sub- 



186 



